Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, April 22, 2024
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
[ Mon, Apr 22nd 2024
] - WOPRAI
Matt Miksic Maintained (ABT) at Buy with Decreased Target to $140 on, Apr 22nd, 2024
Matt Miksic of Barclays, Maintained "Abbott Laboratories" (ABT) at Buy with Decreased Target from $141 to $140 on, Apr 22nd, 2024.
Matt has made no other calls on ABT in the last 4 months.
There are 4 other peers that have a rating on ABT. Out of the 4 peers that are also analyzing ABT, 0 agree with Matt's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Matt
- Shagun Singh of "RBC Capital" Maintained at Buy with Decreased Target to $125 on, Thursday, April 18th, 2024
- Vijay Kumar of "Evercore ISI Group" Maintained at Buy with Increased Target to $125 on, Thursday, April 4th, 2024
- Joanne Wuensch of "Citigroup" Maintained at Strong Buy with Increased Target to $128 on, Wednesday, April 3rd, 2024
- Jayson Bedford of "Raymond James" Maintained at Buy with Increased Target to $127 on, Thursday, January 25th, 2024
